We evaluated the efficacy and safety of amlodipine besylate alone or in combination with other antihypertensive agents in high-risk hypertensive patients in Spanish primary care. In this 1-year, open-label, prospective cohort study, 7468 patients were treated with amlodipine 5 -10 mg as a monotherapy or as an add-on therapy to attain blood pressure control (target of < 140/90 mmHg or, in patients with conditions such as diabetes or chronic kidney disease, < 130/85 mmHg). At 12 months, the primary outcome (change from baseline in predicted 10-year coronary heart disease risk) was -8.6%, down from 24.7% at baseline (relative risk reduction, 31.6%). Change in blood pressure from baseline (162.5/95.3 mmHg) was -26.7/ -14.6 mmHg, and 38.6% of patients achieved their blood pressure target. In summary, significant reductions in predicted coronary heart disease risk and blood pressure were observed with amlodipine both as a monotherapy and as an add-on therapy. Amlodipine was well tolerated and compliance with treatment was good.
Introduction
Cardiovascular disease (CVD) continues to be a common cause of death in Western countries, including Spain. 1,2 Numerous prospective studies have demonstrated a correlation between the incidence of hypertension and CVD and renal failure, 3 -6 and lowering blood pressure (BP) is associated with a decreased incidence of cardiovascular morbidity and mortality, and overall mortality, 7 -10 down to at least 115/75 mmHg. 11 Patients at high cardiovascular risk, such as those with diabetes or renal disease, benefit from lower BP targets than others. 11 -14 Despite guidelines outlining antihypertensive treatment strategies, 13 -15 it is estimated that J Zamorano, L Rodriguez Padial, J Cosín et al.
The CORONARIA study only 31% of the US hypertensive population, 16 and as few as 5% -10% of the hypertensive patients in some European countries 17 achieve their recommended BP targets. A recent study in a Spanish primary care setting revealed that only approximately one-quarter of hypertensive patients achieve their BP target. 18 In addition to hypertension, risk factors for CVD and coronary heart disease (CHD) include high levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), low levels of high-density lipoprotein cholesterol (HDL-C), cigarette smoking, diabetes, obesity, left ventricular hypertrophy (LVH) and a family history of CHD/CVD. 19 -22 Data from population studies, such as the Framingham Heart Study, 23, 24 have led to the development of algorithms that predict CHD risk for individual patients, based on their risk factors. 24 Guidelines for preventing CVD use measures such as algorithm scores to identify patients requiring treatment. 15, 25 The scores may also be used to assess the impact of risk factor management on overall CHD or CVD risk, although they were not designed for this purpose.
The primary objective of this study was to evaluate the effect of optimal BP control using the calcium channel blocker (CCB) amlodipine besylate, alone or in combination with other antihypertensive agents, on predicted CHD risk in high-risk patients with hypertension in Spain. The 10year risk of CHD was calculated using an algorithm derived from the Framingham Heart Study. 24 The secondary objectives were to evaluate the changes in BP, lipid profile, heart rate, treatment compliance and lifestyle after 2, 6 and 12 months of amlodipine therapy, either alone or in combination with other antihypertensive agents. An important aspect of this investigation was to evaluate whether there was a difference in the treatment effect when amlodipine was used as a monotherapy or as an add-on therapy to different classes of antihypertensive agent.
Patients and methods
This was a 1-year, non-randomized, openlabel, observational, prospective cohort study conducted in primary care centres throughout 17 autonomic communities in Spain (providing a sample that was representative of the overall Spanish population) between January 2001 and October 2002.
PATIENTS
To be eligible for inclusion in the study, patients (male or female) were required to be aged ≥ 18 years with hypertension, defined according to the 1999 World Health Organization (WHO)-International Society of Hypertension (ISH) guidelines 26 (BP > 140/90 mmHg or in patients with diabetes, nephropathy, retinopathy, CVD, peripheral arteriopathy, stroke, LVH or congestive heart failure, > 130/85 mmHg), who visited one of the primary care centres included in the study for BP control. As well as hypertension, they were required to have at least one other cardiovascular risk factor (age > 55 years for men and > 65 years for women, smoking, TC > 6.5 mmol/l [> 250 mg/dl], diabetes [defined according to Wilson et al. 24 ], CVD or a family history of CVD before the age of 50). Female patients were excluded from the study if they were pregnant or lactating, were not using adequate contraception, or were < 2 years post-menopausal and had not been surgically sterilized. Patients with any of the contraindications for amlodipine treatment listed in the Summary of Product Characteristics 27 were also excluded from the study.
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STUDY DESIGN
Patients were assigned amlodipine besylate 5 mg once daily as initial monotherapy in place of previous monotherapy, or in addition to any number of existing antihypertensive therapies (including prior CCBs), and were assessed at 2, 6 and 12 months. Those receiving amlodipine prior to study entry were assigned amlodipine 10 mg once daily at baseline. Patients who did not meet their target BP (< 140/90 mmHg or, in patients with conditions such as diabetes or chronic kidney disease, < 130/85 mmHg) 26 at any time during the study had their amlodipine dosage increased to 10 mg once daily, or were treated with an additional antihypertensive agent at the discretion of their physician. It should be noted that since this study was carried out, the WHO-ISH, 14 and the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) 13 guidelines have been revised to include a target BP of < 130/80 mmHg in patients with conditions such as diabetes or kidney disease, rather than < 130/85 mmHg. The Joint European guidelines for CVD prevention also emphasize this lower BP target for patients with diabetes. 15 Similarly, the definition of diabetes was updated in the 2003 American Diabetes Association (ADA) guidelines 28 and differs slightly to the definition used in this study. 24 The study was conducted according to the Declaration of Helsinki 1989 (South African Update), in compliance with European and Spanish regulations on post-authorization safety studies, and all patients gave written, informed consent to be included in the study.
EVALUATION OF EFFICACY
The primary endpoint was the percentage change from baseline in predicted 10-year CHD risk at 12 months. Prediction of CHD risk was calculated using a Framingham equation. 24 Secondary endpoints included: the absolute change from baseline in the predicted 10-year CHD risk at 6 months; the percentage of patients who achieved their target BP; the mean change from baseline in systolic BP (SBP), diastolic BP (DBP) and heart rate at each visit; and the percentage change from baseline in TC, LDL-C, HDL-C and triglycerides (TGs) at 6 and 12 months. Treatment compliance and compliance with recommended lifestyle changes (low salt, low saturated fat diet; regular exercise [> 30 min/day for at least 5 days/week]; low-tomoderate alcohol consumption [< 2 units/week]) were assessed at each visit. All efficacy data were analysed globally and were also analysed according to amlodipine dose, as follows: group 1, those who received 5 mg once daily throughout the study; group 2, those who received 5 mg once daily titrated to 10 mg once daily at 6 months; group 3, those who received 5 mg once daily titrated to 10 mg once daily after 2 months; and group 4, those who received 10 mg once daily throughout the study. Finally, the BPlowering effects of amlodipine alone and when added to monotherapy with other drug classes were compared.
EVALUATION OF SAFETY
Safety was evaluated by means of physical examination and adverse events (defined as adverse drug reactions, illnesses and symptoms with onset during the study, or exacerbations of pre-existing illnesses) were recorded at months 2, 6 and 12. Serious adverse events included any drug reaction that resulted in death, in-patient hospitalization, congenital anomaly/birth defect, or any event that was life-threatening or required medical/surgical intervention. Objective test findings (such as J Zamorano, L Rodriguez Padial, J Cosín et al. The CORONARIA study electrocardiogram changes, abnormal laboratory test results) that resulted in a change to study drug dosage or discontinuation, or that required intervention or diagnostic evaluation to assess the patient's risk were reported as adverse events or serious adverse events, as appropriate. Suspected or causal relationship with study treatment was also recorded. Specifically, the incidence of oedema with the different drug combinations was compared.
CLINICAL AND LABORATORY ASSESSMENTS
A sphygmomanometer was used to measure BP after a sitting rest of at least 5 min, with the mean of two consecutive measurements used for analyses. Where possible, BP was measured at each visit by the same person at the same arm. Blood samples were taken at each visit, and lipid profiles and blood glucose levels were determined according to the methods used by the individual clinics. Height and weight were measured from which body mass index was calculated. Treatment compliance was assessed by counting the number of amlodipine tablets that were not taken. Lifestyle changes were assessed with a questionnaire developed by the investigators.
STATISTICAL ANALYSIS
The primary analysis of efficacy and all secondary and safety outcomes were based on the intent-to-treat (ITT) population (all patients who received at least one dose of study medication, employing a last observation carried forward analysis).
The primary endpoint, the change from baseline for each individual group and the change from baseline between groups in SBP, DBP, heart rate, TC, LDL-C, HDL-C and TGs, were evaluated by analysis of covariance with terms for the effects of the Spanish community and baseline values. The analyses were carried out using the Statistical Analysis System (SAS ® ) PROC GLM procedure (SAS ® Institute, Cary, NC, USA). The percentage of patients reaching their target BP at each visit was analysed using logistic regression with a model that accounted for the effects of the Spanish community and baseline values, and with adjustment for the number of comparisons. This analysis was undertaken using the PROC LOGISTIC SAS ® procedure (SAS ® Institute).
Descriptive statistics were performed, including measurements of central tendency and dispersion for the quantitative variables and absolute and relative frequencies, with their 95% confidence intervals in both cases. It was assumed that a 40% relative-risk difference in absolute predicted 10-year CHD risk between baseline and 12 months would be clinically significant, and that an initial sample size of 376 patients per Spanish community (6392 patients in 17 communities) would be sufficient for a power of 0.8 with twotailed testing at the 0.05 level of significance.
Results

PATIENT DISPOSITION AND BASELINE CHARACTERISTICS
A total of 7728 patients were assigned to study medication, 7468 (96.6%) of whom received at least one dose of study medication and were included in the ITT population and, of these, 5901 (76.4%) completed the study. The patients' mean age was 63.6 years and 51.4% were male (Table  1) . At baseline, mean BP was 162.5/95.3 mmHg, mean LDL-C was 4.05 mmol/l (156.6 mg/dl), mean predicted 10-year risk of CHD was 24.7%, 59.9% of patients were prescribed amlodipine monotherapy and 33.0% of patients were receiving lipidlowering therapies, most commonly atorvastatin (Table 1) .
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The CORONARIA study The median duration of treatment was 331 days. In total, 4292 (57.5%) patients were receiving antihypertensive therapy before entering the study, but none was at target BP at baseline. Treatment compliance was generally good: after 12 months of treatment, 86.4% of patients were taking 80% -120% of their study medication; 12.1% were taking 50% -79%; and only 1.5% were taking < 50% or > 120%, as prescribed. Table 2 provides details of patients completing and not completing the study.
In terms of amlodipine dosing, 43.4% of patients were categorized into group 1, 5.3% into group 2, 17.2% into group 3 and 34.0% into group 4. The proportions of patients taking one, two and three or more antihypertensive drugs in addition to amlodipine are shown in Table 3 . The proportion of patients on amlodipine monotherapy decreased from 59.9% in months 0 -2 to 54.0% in months 6 -12 (Table 3) . Thiazide diuretics were the most commonly used class of concomitant antihypertensive drugs, with 21.4% of patients receiving these at 6 -12 months, followed by angiotensin converting enzyme (ACE) inhibitors (Table 4 ).
EVALUATION OF EFFICACY
The primary endpoint, the change from baseline in predicted 10-year CHD risk at 12 reduced in all four treatment groups with no significant differences between groups (P > 0.05 for relative risk reductions between groups at 12 months; Fig. 1 ). Overall, after 2 and 6 months, the calculated total CHD risk 24 in patients (n = 7468) receiving different doses of amlodipine as either a monotherapy or in addition to other antihypertensive agents over 12 months. Group 1 (43.4% of patients) received amlodipine 5 mg once daily throughout the study; group 2 (5.3%) received 5 mg once daily titrated to 10 mg once daily at 6 months; group 3 (17.2%) received 5 mg once daily titrated to 10 mg once daily after 2 months; and group 4 (34.0%) received 10 mg once daily throughout the study. P < 0.0001 for all groups at 2, 6 and 12 months versus baseline; P > 0.05 between groups at 12 months was reduced by 3.9% ± 5.1% (relative risk, -16.4% ± 18.5%) and 7.4% ± 9.0% (relative risk, -27.2% ± 28.1%), respectively (P < 0.0001 versus baseline for both). The reduction from baseline in predicted CHD risk at 12 months was significantly greater in females than males (P < 0.0001), in smokers than non-smokers (P = 0.0085), in diabetics than non-diabetics (P = 0.0018), in patients who had not previously been treated for hypertension than those who had (P < 0.0001), in patients receiving amlodipine as antihypertensive monotherapy than those who received add-on therapy (P < 0.0001), and in patients receiving lipid-lowering therapy than in those not receiving it (P < 0.0001) ( Table 5 ). When patient data were grouped into quartiles based on predicted CHD risk at baseline, the greatest reduction over the 12-month study period was seen in those in quartile 4, i.e. those with the greatest risk of developing CHD over 10 years at baseline (Fig. 2) .
After 12 months, both SBP (-26.7 ± 15.3 mmHg) and DBP (-14.6 ± 10.2 mmHg) were significantly reduced from baseline (162.5/95.3 mmHg) in the overall cohort (P < 0.0001 for both), and 38.6% of patients achieved their BP target. There was no significant difference between dosage groups in the level of BP reduction (Fig. 3A, 3B ) or in the proportion of patients who achieved their target BP at 12 months (Fig. 3C) , indicating that up-titration and add-on therapy was appropriately used in the more difficult-to-treat patients.
In patients who had not achieved their target BP using monotherapy with other drugs at baseline, the addition of amlodipine significantly (P < 0.0001) reduced both SBP and DBP after 2, 6 and 12 months compared with baseline and the reductions were similar irrespective of the class of agent to which amlodipine was added (mean changes in SBP at 12 months were -27 mmHg with ACE inhibitors, -24 mmHg for angiotensin receptor blockers [ARBs], -25 mmHg for α-blockers, -26 mmHg for CCBs, -23 mmHg for thiazide diuretics, -26 mmHg for β-blockers and -29 mmHg for J Zamorano, L Rodriguez Padial, J Cosín et al.
The CORONARIA study Group 1 (43.4% of patients) received amlodipine 5 mg once daily throughout the study; group 2 (5.3%) received 5 mg once daily titrated to 10 mg once daily at 6 months; group 3 (17.2%) received 5 mg once daily titrated to 10 mg once daily after 2 months; and group 4 (34.0%) received 10 mg once daily throughout the study. P < 0.0001 for all groups for all three parameters at 2, 6 and 12 months versus baseline Fig. 4A ). The proportion of these patients achieving their BP goal following the addition of amlodipine also increased throughout the study regardless of the class of monotherapy (Fig. 4B) . BP was significantly reduced from baseline in patients receiving amlodipine plus none, one, two, or three or more agents at 12 months (P < 0.0001; Fig. 5A ). Similar BP reductions in clinical terms (albeit significantly different statistically) were achieved in patients who only needed amlodipine monotherapy (-27.1/-14.8 mmHg at 12 months) versus the more difficult to treat patients who needed combination therapy (-26.1/-14.3 mmHg at 12 months; P < 0.0001 and P = 0.0008 for SBP and DBP, respectively). However, the proportion of patients who achieved their target BP at 12 months decreased as the number of additional antihypertensive agents increased (Fig. 5B ). This trend was statistically significant (P < 0.0001). Between baseline and 12 months, patients' lifestyle changes all improved significantly (P < 0.0001) as follows: adherence to a low-salt diet, from 73.3% to 82.2%; adherence to a low-fat diet, from 61.4% to 71.6%; regular physical exercise, from 45.7% to 58.3%; and moderated alcohol intake, from 60.0% to 65.5%. Lipid profiles also improved significantly (P < 0.0001) (Table 6 ). Although the reduction in heart rate at each time-point was also statistically significant versus baseline (P < 0.0001), the changes were considered too small to be of clinical importance.
EVALUATION OF SAFETY
Amlodipine treatment was well tolerated. A total of 431 adverse events were reported by 416 patients (5.6% of the ITT study population; n = 7468). Of these, 275 patients (3.7%) were considered by the investigators to have experienced amlodipine-related events. The majority (90%) of events were mild-to-moderate in nature, the most common being oedema (254 patients, 3.4%), headache (29 patients, 0.4%), flushing (17 patients, 0.2%), dizziness (six patients, 0.1%) and diarrhoea (five patients, 0.1%). Serious adverse events were reported by 32 patients (0.4%), none of which was considered to be treatment related. Only 90 patients (1.2%) discontinued their study medication due to adverse events, 66 of which were attributed to amlodipine. The incidence of oedema did not differ significantly when amlodipine was co-administered with an ACE inhibitor, ARB, α-blocker, thiazide diuretic, another CCB, β-blocker or vasodilator (Fig. 6 ).
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The CORONARIA study FIGURE 5: (A) Systolic (SBP) and diastolic blood pressure (DBP) reductions: P < 0.0001 for all groups for all decreases in SBP and DBP; P < 0.0001 for SBP and P = 0.0008 for DBP at 12 months for amlodipine monotherapy versus combination therapy for the change from baseline for each individual group; significances for the between-group changes from baseline are shown in the figure (NS, not statistically significant [P > 0.05]). (B) The percentage of patients achieving their target BP increases for all groups at 2, 6 and 12 months versus baseline (P < 0.0001 for all groups/time points); the proportion of patients who achieved their target BP at 2, 6 and 12 months decreased significantly as the number of additional antihypertensive agents increased (P < 0.0001 for trend). See Table 3 for the percentage of patients in each group at each stage 
Discussion
In this study, amlodipine 5 -10 mg once daily, both alone and in combination with other antihypertensive agents, was associated with considerable (31.6%) relative risk reduction in Framingham predicted 10year CHD risk in high-risk patients with hypertension in Spain. The Framingham equation is most accurately applied to sample groups with similar characteristics and may overestimate the absolute risk for CHD in low-risk (Mediterranean) European populations. 29, 30 The unadjusted Framingham total risk estimate in a Spanish population should, therefore, be treated with caution, whereas the change in relative risk is less sensitive to the absolute level of baseline risk. 31 -33 It should be noted as a limitation of this analysis that Framingham calculations were not designed to assess the effects of therapeutic interventions.
Nonetheless, we believe that Framingham is a useful tool for evaluating the potential reductions in overall CHD risk that may be achieved if improvements in risk factors are maintained over the long term. In addition, the Framingham equation has been used previously in other Spanish studies, including those evaluating antihypertensives. 34 -36 After 12 months of amlodipine treatment, the mean reduction in predicted CHD risk was similar for all amlodipine dosing strategies. The same was also true for SBP, DBP and the percentage of patients who achieved their target BP, which were the main determinants of the calculated risk reduction. As expected, the greatest absolute and relative risk reductions were observed in patients with the highest baseline CHD risk, for example, smokers, diabetics or patients with previously untreated hypertension. Furthermore, patients who were treated with both antihypertensive and lipid-lowering therapies benefited more than those receiving only antihypertensive therapy. This was expected because the Framingham equation includes information on LDL-C and HDL-C, 24 as well as other cardiovascular risk factors. Indeed, dyslipidaemia and hypertension interact in a multiplicative rather than an additive manner to increase the occurrence of CHD in comparison with patients with just one of these risk factors. 37, 38 Although the predicted risk reduction in this study can largely be attributed to amlodipine, a reduction in BP and improvements in lipid profile due to lifestyle changes as well as smoking cessation are also likely to have played a role. As a result, the absolute effect of amlodipine on predicted CHD risk cannot be determined precisely.
Significant reductions from baseline in BP and predicted CHD risk were observed in all patients, irrespective of whether they received amlodipine alone or in combination with previous therapies, including ACE inhibitors, ARBs, β-blockers and thiazide diuretics. These results are consistent with those from Bisognano et al. 39 who conducted a retrospective analysis of 1175 hypertensive adults in which treatment with amlodipine was associated with incremental reductions in SBP and DBP across all patient groups, irrespective of previous therapy.
The number of patients who achieved their target BP increased significantly throughout the study. This might be attributable to the BP-lowering efficacy of amlodipine as an add-on therapy, as well as the well-defined treatment strategy used here in which the dose of amlodipine was uptitrated, or additional agents were used, at predetermined follow-up times in order to reach the treatment goals. In clinical practice, BP remains uncontrolled in much of the hypertensive population, including over two-thirds of Spanish patients with hypertension. 16 -18,34 One reason for this is lack of physician awareness, 40 -43 which is often confounded by unclear and conflicting treatment guidelines. Most guidelines stress the need for two or more antihypertensive medications in the majority of patients and highlight the importance of uptitrating doses to useful therapeutic levels. 13, 14 In practice, however, physicians frequently lack knowledge on how and when this should be done. 41 This study contributes to the increasing volume of evidence demonstrating the benefits of simple, welldefined antihypertensive treatment strategies.
Persistence with treatment throughout this study was lower than expected, with 23.6% of patients discontinuing treatment with amlodipine during the 12-month study period, compared with only 12.4% in the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). 8 This appeared to be unrelated to adverse events, as only 90 patients (1.2%) discontinued their study medication due to these. Furthermore, amlodipine has been shown to be well tolerated in a broad range of patients, with few side-effects. 8,9,44 -46 A review of pharmaceutical databases has revealed that persistence with antihypertensive therapy by patients already receiving treatment is higher than in patients who had not been previously treated and that, in clinical practice, the number of patients who continue their medication after 1 year can vary widely (between 5% and 75%). 47 Given that 90% of ALLHAT 8 patients were receiving antihypertensive therapy at baseline, compared with only 58% in the present study, the sample population in this study is J Zamorano, L Rodriguez Padial, J Cosín et al.
The CORONARIA study likely to be more representative of clinical practice rather than the controlled environment of clinical trials such as ALLHAT, and this might explain the higher drop-out rate. Furthermore, observational cohort studies, such as the present study, tend to experience more drop-outs than more stringently controlled prospective, randomized, double-blind clinical trials.
The death rate during the study (3.1 per 1000 patient years) was as expected considering the age and comorbid conditions in this population, and was similar to the rate seen in ALLHAT. 8 None of these deaths was attributed to study medication. The most commonly observed adverse event in amlodipine-treated patients was peripheral oedema and its incidence was not significantly worsened when amlodipine was used in combination with other antihypertensives. Other studies have suggested that a combination of CCBs with ACE inhibitors reduces the incidence of oedema. 48 The results of the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) provide strong support for the use of amlodipine. 44 In this study, an amlodipine-based regimen resulted in significant reductions compared with an atenolol-based regimen in major cardiovascular endpoints in hypertensive patients who had three or more additional risk factors. 44 Compared with the atenololbased regimen, fewer individuals on the amlodipine-based regimen had a primary endpoint (non-fatal myocardial infarction, including silent myocardial infarction and fatal CHD [reduced by 10%, P = 0.1052]). 44 For all-cause mortality, a significant reduction of 11% (P = 0.025) was seen with amlodipine/perindopril versus atenolol/ thiazide. 44 Significant differences were also seen for fatal and non-fatal stroke (reduced by 23%, P = 0.0003), all cardiovascular events and procedures (reduced by 16%, P = 0.0001), cardiovascular mortality (reduced by 24%, P = 0.0001) and new-onset diabetes in patients administered amlodipine-versus atenolol-based therapy. 44 Although the difference in the primary endpoint was not significant, it should be noted that the study was stopped prior to reaching the prespecified number of endpoints due to the significant reductions in all-cause and cardiovascular mortality.
The results of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial 9 renounce the previous perception that a CCB combined with a thiazide diuretic is less potent than other combinations. 49 In this study amlodipine combined with a thiazide diuretic was associated with good BP control. 9 The trial assessed whether, for the same BP-lowering effect, regimens based on amlodipine or valsartan would have differing effects on cardiovascular endpoints in high-risk hypertensive patients. 9 There were significant differences in BP favouring amlodipine throughout the trial, especially in the early months, which had major effects on outcomes. 9 In coronary artery disease patients whose BP at baseline was well controlled, as studied in the Comparison of AMlodipine vs Enalapril to Limit Occurrences of Thrombosis (CAMELOT) trial, amlodipine-based treatment resulted in a significant (31%) reduction in the relative risk of having a major cardiovascular event compared with placebo (P = 0.003). 45 Interestingly, enalapril-based therapy was not significantly different from placebo. 45 Together with the findings described here, these results demonstrate that amlodipine is an effective therapy in patients with hypertension whether initiated alone or added to an existing antihypertensive treatment regimen.
